Pediatrics

doi: https://dx.doi.org/10.25005/2074-0581-2017-19-1-68-72
MORPHOFUNCTIONAL AND CYTOCHEMICAL PARALLELS IN HEREDITARY HAEMOLYTIC ANAEMIA IN CHILDREN

S.N. Davlatova, K.I. IsmoIlov, Z.a. MuhItdInova, l.M. SolIeva

Department of Pediatric Diseases № 2, Avicenna Tajik State Medical University, Dushanbe, Tajikistan
National Medical Center of the Republic of Tajikistan, Dushanbe, Tajikistan

Objective: To study metabolic alterations in the organisms of children with hereditary hemolytic anemia (HHA).

Methods: Authors studied metabolic conditions in 54 children aged 3 to 15 years suffering from HHA: deficit of glucose-6-phosphate dehydrogenase, thalassemia, genetic microspherocytocis. Metabolism research was carried out based on electrocardiographic, echocardiographic, and cytochemical methods.

Results: It has been established that 96.3% of children with HHA had the signs of myocardial dystrophy. Analysis of echocardiogram shows heart cavity dilation (primarily left heart) and lower ejection fraction (55.2±1.6%). Analysis of cytochemical status of peripheral blood lymphocytes shows arrest of activity of energetic metabolism enzymes – succinate dehydrogenase (up to 11.54±0.25) and alpha-glycerophosphatedehydrogenase (up to 5.37±0.21).

Conclusions: Results of performed laboratory and instrumental research methods show crude metabolic disturbances in children with HHA explained by the chronic hemic hypoxia, hemosyderosis of internals, and reduced activity of intracellular dehydrogenase.

Keywords: Hereditary hemolytic anemia, hypoxia, myocardial dystrophy, metabolic disorders.

Download file:


References
  1. Sheffman FD. Patofiziologiya krovi [Pathophysiology of blood]. Moscow, RF: Binom; 2009. 448 p.
  2. Patrick G, Gallagher PG. Abnormalities of the Erythrocyte Membrane. Pediatr Clin North Am. 2013;60(6):1349-62. Available from: http://dx.doi/10.1016/j.pcl.2013.09.001
  3. Koralkova P, van Solinge WW, van Wijk R. Rare hereditary red blood cell enzymopathies associated with hemolytic anemia – pathophysiology, clinical aspects, and laboratory diagnosis. Int J Lab Hematol. 2014;36(3):388-97. Available from: http://dx.doi/10.1111/ijlh.12223.
  4. Sokolova TA. Geneticheskie aspekty nasledstvennykh gemoliticheskikh anemiy [Genetic aspects of hereditary hemolytic anemia (enzymopathies)]. Uspekhi sovremennogo estestvoznanya. 2012;10:34-42.
  5. Alekseev NA. Gematologiya i immunologiya detskogo vozrasta [Hematology and immunology of childhood]. Moscow, RF: Hippocrat; 2009. 1039 p.
  6. Berghout J, Higgins S, Loucoubar C, Sakuntabhai A, Kain KC. Genetic diversity in human erythrocyte pyruvate kinase. Genes Immun. 2012;13(1):98-102. Available from: http://dx.doi/10.1038/gene.2011.54.
  7. Janz TG, Hamilton GC. Anemia, polycythemia, and white blood cell disorders. In: Marx JA, Hockberger RS, Walls RM, et al, eds. Rosen’s Emergency Medicine: Concepts and Clinical Practice. 8th ed. Philadelphia, PA: Elsevier Saunders; 2014: chap 121. p. 1586-1605.
  8. Nagornaya NV, Vilchevskaya EV, Bordyugova EB, Dudchak AP, Marchenko EN, Yuldasheva SA. Gemoliticheskie amemii u detey [Hemolytic anemia in children]. Symposium nomer 158. Novosty meditsiny i farmatsii (spetsialnyy portal dlya medrabotnikov). 2016.
  9. Kuznik BI, Макsimova ОG. Klinicheskaya gematologiya detskogo vozrasta [Clinical hematology of childhood]. Moscow, RF: Vuzovskaya kniga; 2010. 496 p.
  10. Vorobyov AI. Rukovodstvo po laboratornoy gematologii [Manual on laboratory hematology]. Moskva, RF: Prakticheskaya meditsina; 2011. 352 p.
  11. Demidova AV. Anemii [Anemias]. Moscow, RF: MEDpress-inform; 2006. 64 p.
  12. Davlatova SN, Ismailov KI, Davlatov MD, Sharipov FS, Kakhhorov ZZ. Osobennosti metabolizma i korrigiruyushchey terapii u detey s nasledstvennymi gemoliticheskimi anemiyami [Features of metabolism and corrective therapy in children with hereditary hemolytic anemia]. Avicenna Bulletin (Vestnik Avitsenny). 2010;1:77-83.
  13. Davlatova SN, Ismailov KI. Adaptatsionnye vozmozhnosti serdechnososudistoy sistemy u detey s nasledstvennymi gemoliticheskimi anemiyami [Adaptation capabilities of the cardiovascular system in children with hereditary hemolytic anemia]. Pediatriya i detskaya khirurgiya Tadzhikistana. 2009;2:11-6.
  14. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7):2973-8.
  15. Breda L, Rivella S. Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production. Hematol Oncol Clin North Am. 2014;28:375-86. Available from:http://dx.doi/10.1016/j.hoc.2013.12.001.
  16. Aydinok Y, Kattamis A, Cappellini MD, E-Beshlawy A, Origa R, Elalfy M et al. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood. 2015;125(25):3868-77. Available from:http://dx.doi/10.1182/blood-2014-07-586677.
  17. Origa R. Beta-Thalassemia. Dipartimento di Sanità Pubblica e Medicina Molecolare Università degli Studi di Cagliari Ospedale Regionale per le Microcitemie. Cagliari, Italy. ti.acinu@agiro.alleaffar Initial Posting [September 28, 2000; Last Update: May 14, 2015].
  18. Bazil А, Keramati МR, Shahramian I. Cardiac Hemosiderosis in Transfusion Dependent Thalassemia: A Mini-Review. Iran. Int J Basic Sci Med. 2017;2(1):5-10. Available from: http://dx.doi/10.15171/ijbsm.2017.02.
  19. Porter JB, Wood J, Olivieri N, Elliott P, Vichinsky, Taher A, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson. 2013;15:38. [Published online 2013 May 20]. Available from: http://dx.doi/10.1186/1532-429X-15-38.
  20. Lobo C, Angulo IL, Aparicio LR, Drelichman GI, Zanichelli MA, Cancado R. Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload – the RELATH study. Hematology. 2011;16(5):265-73. PMID: 21902889. Available from: http://dx.doi/10.1179/102453311X13085644680302.
  21. Shen J, Porter BJ. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood. 2015;25(25): 3868-77. Available from: http://dx.doi/10.1182/blood-2014-07-586677. Shen J, Porter BJ. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood. 2015;25(25): 3868-77. Available from: http://dx.doi/10.1182/blood-2014-07-586677.
  22. Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur J Haematol. 2015;95(5):411-20. Available from: http://dx.doi/10.1111/ejh.12507.

Authors informations:

Davlatova Sohira Nozirovna, Candidate of Medical Sciences, Associate Professor of the Department of Pediatric Diseases № 2 at Avicenna Tajik State Medical University

Ismoilov Komildjon Isroilovich, Doctor of Medical Sciences, Full Professor, Head of the Department of Pediatric Diseases № 2 at Avicenna Tajik State Medical University

Muhitdinova Zumrad Abubakrovna, Candidate of Medical Sciences, Associate Professor of the Department of Pediatric Diseases № 2 at Avicenna Tajik State Medical University

Solieva Lola Mirsaidovna, pediatrician at National Medical Center of the Republic of Tajikistan

Address for correspondence:

Davlatova Sohira Nozirovna

Candidate of Medical Sciences, Associate Professor of the Department of Pediatric Diseases № 2 at Avicenna Tajik State Medical University

734003, Republic of Tajikistan, Dushanbe, Rudaki Avenue 139,

Phone: (+992) 935 277539

E-mail: sokhira@mail.ru

Materials on the topic: